Sacral neuromodulation in a patient with pseudocholin-esterase deficiency

Nadia N. Megahed, MD, Prapti Singh, MD, Yaseen Maleki, MD, James F. Kirby, MD, Julie N. Stewart, MD

1. Houston Methodist Hospital, Houston, TX, USA
2. Washington University in St Louis, Saint Louis, MO, USA
3. Southeast Texas OB/GYN Associates, Beaumont, TX, USA
4. Texas A&M College of Medicine, Bryan, TX, USA

Abstract

PURPOSE: To bring attention to a genetic condition that could play a role in management of third line therapies for overactive bladder (OAB).

CASE REPORT: We present a case of a 56-year-old patient with a history of refractory OAB who underwent a stage I sacral neuromodulation (SNM) procedure and was unable to elicit the appropriate S3 motor responses while sedated. Further review of medical history revealed patient was a pseudocholinesterase (PChE) deficiency carrier. The patient ultimately had the device removed due to suboptimal improvement in lower urinary tract symptoms.

CONCLUSION: This is the first case report of a PChE deficiency carrier who underwent SNM. A diagnosis of PChE deficiency or carrier status should be considered when unable to elicit sacral motor response during lead placement.